|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 9.895 USD | +0.12% |
|
-1.04% | +3.94% |
| 05-22 | BioSyent Inc., Q1 2026 Earnings Call, May 14, 2026 | |
| 05-19 | BioSyent Secures Health Canada Nod For Hypothyroidism Oral Solution | MT |
| Market Cap | 160M 113M 99M 91.48M 85.39M 10.71B 162M 1.09B 422M 5.26B 425M 416M 18.28B | P/E 2026 * |
15.7x | P/E 2027 * | 13x |
|---|---|---|---|---|---|
| Enterprise Value | 160M 113M 99M 91.48M 85.39M 10.71B 162M 1.09B 422M 5.26B 425M 416M 18.28B | EV / Sales 2026 * |
2.32x | EV / Sales 2027 * | 1.95x |
| Free-Float |
64.5% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: BioSyent Inc.
| 1 day | +0.12% | ||
| 1 week | -1.04% | ||
| Current month | -2.60% | ||
| 1 month | -2.02% | ||
| 3 months | -11.96% | ||
| 6 months | +11.81% | ||
| Current year | +3.94% |
| 1 week | 9.85 |  | 10 |
| 1 month | 9.81 | | 10.23 |
| Current year | 9 | | 12 |
| 1 year | 7.63 | | 12 |
| 3 years | 5.49 | | 12 |
| 5 years | 4.69 | | 12 |
| 10 years | 2.15 | | 12 |
| Manager | Title | Age | Since |
|---|---|---|---|
René Goehrum
CEO | Chief Executive Officer | 66 | 1999-04-30 |
Robert March
DFI | Director of Finance/CFO | - | 2018-09-09 |
Navid Ashrafi
CTO | Chief Tech/Sci/R&D Officer | - | 2015-05-31 |
| Director | Title | Age | Since |
|---|---|---|---|
Sara Elford
BRD | Director/Board Member | 55 | 2018-01-07 |
Prakash Gowd
BRD | Director/Board Member | 62 | 2025-05-14 |
René Goehrum
CHM | Chairman | 66 | 1999-05-31 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +0.12% | -1.04% | - | - | 113M | |
| +0.32% | -2.73% | +44.49% | +143.28% | 980B | |
| +1.27% | -3.98% | +54.41% | +41.13% | 550B | |
| +6.25% | +1.00% | +24.13% | +68.06% | 382B | |
| +0.25% | -3.09% | +23.33% | +16.78% | 316B | |
| +0.42% | -1.28% | +27.89% | +14.71% | 272B | |
| +1.67% | -1.47% | +26.76% | +32.88% | 268B | |
| +2.39% | +4.42% | -36.96% | -45.12% | 199B | |
| +2.11% | -2.95% | +19.14% | +51.83% | 182B | |
| +0.90% | -0.57% | +15.09% | +60.89% | 154B | |
| Average | +0.69% | -2.70% | +22.03% | +42.72% | 366.93B | |
| Weighted average by Cap. | +0.38% | -3.50% | +31.28% | +65.69% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 69M 48.71M 42.66M 39.42M 36.79M 4.61B 69.66M 469M 182M 2.27B 183M 179M 7.87B | 82.3M 58.1M 50.88M 47.02M 43.89M 5.5B 83.09M 559M 217M 2.7B 218M 214M 9.39B |
| Net income | - | - |
| Net Debt | - | - |
Employees
-
Sector
Pharmaceuticals
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-06-22 | 9.895 $ | +0.12% | 32,212 |
| 26-06-18 | 9.884 $ | +0.35% | 3,454 |
| 26-06-17 | 9.850 $ | -0.91% | 309 |
| 26-06-16 | 9.940 $ | -0.70% | 271 |
Sell
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
14.00CAD
Average target price
18.00CAD
Spread / Average Target
+28.57%
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- RX Stock
- BIOYF Stock
Select your edition
All financial news and data tailored to specific country editions
